Affordable hypertension therapy for diabetic patients.

摘要

Type 2 diabetes is one of the most expensive chronic diseases to treat, and in South Africa, with prescribed minimum benefits (PMB) applying to this disease, both private and public-sector flinders are on the alert for cost-benefit issues. Perhaps one of the cost-benefit issues flinders have missed is the current and future savings that can be made with effective anti-hypertension therapy from the outset at diabetes diagnosis.Achievement of blood pressure goals early in a patient's blood pressure-control strategy influences compliance. In a study of blood pressure treatment in a health maintenance organisation (HMO) in the United States, changes in anti-hypertensive therapy were investigated in patients whose initial therapy was angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor Mockers (ARBs) or calcium channel blockers (CCBs).